Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26,714.86% | 89.10% | 912.38% | 22.49% | -71.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26,714.86% | 89.10% | 912.38% | 22.49% | -71.28% |
| Cost of Revenue | 41.40% | 22.40% | 10.18% | 2.52% | -4.32% |
| Gross Profit | 42.30% | -21.71% | 7.93% | -2.43% | 3.62% |
| SG&A Expenses | 29.31% | 26.09% | 41.31% | 41.24% | 27.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.69% | 23.72% | 20.82% | 15.18% | 6.11% |
| Operating Income | 14.34% | -23.29% | -9.12% | -15.16% | -6.66% |
| Income Before Tax | 6.24% | -18.97% | -9.59% | -24.05% | -11.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.24% | -18.97% | -9.59% | -24.05% | -11.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.24% | -18.97% | -9.59% | -24.05% | -11.41% |
| EBIT | 14.34% | -23.29% | -9.12% | -15.16% | -6.66% |
| EBITDA | 14.51% | -23.75% | -12.86% | -14.93% | -6.30% |
| EPS Basic | 14.27% | -2.34% | 8.06% | -1.27% | 2.34% |
| Normalized Basic EPS | 14.27% | -2.33% | 8.06% | -1.26% | 2.33% |
| EPS Diluted | 14.27% | -2.34% | 8.06% | -1.27% | 2.34% |
| Normalized Diluted EPS | 14.27% | -2.33% | 8.06% | -1.26% | 2.33% |
| Average Basic Shares Outstanding | 9.35% | 16.26% | 19.19% | 22.50% | 14.08% |
| Average Diluted Shares Outstanding | 9.35% | 16.26% | 19.19% | 22.50% | 14.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |